Marinus Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview

Marinus Pharmaceuticals

03/11/2023 17:54

* Marinus Pharmaceuticals Inc  MRNS.OQ   MRNS.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The Radnor Pennsylvania-based  company is expected to
report  a
170.6% increase in revenue to $6.332 million from $2.34 million
a year ago, according to the mean estimate from 11 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Marinus
Pharmaceuticals
Inc is for a loss of 66 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $20.5​, above​ its last closing price
of $6.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.69       -0.72      -0.61     Beat    14.9
 Mar. 31 2023  -0.71       -0.72      -0.67     Beat    7.3
 Dec. 31 2022  -0.66       -0.70      -0.76     Missed  -9.1​
 Sep. 30 2022  0.54        0.47       -0.94     Missed  -301.2
 ​​Jun.        -0.64       -0.69      -1.06     Missed  -54.7
 30 2022                                                
 Mar. 31 2022  -0.85       -0.85      -0.52     Beat    38.8​
 Dec. 31 2021  -0.72       -0.76      -0.77     Missed  -1.2
 Sep. 30 2021  -0.73       -0.73      -0.53     Beat    27.6
 This summary was machine generated November 3 at 17:54 GMT.  All
figures in US dollars  unless otherwise stated